<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Optic neuritis: Pathophysiology, clinical features, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Optic neuritis: Pathophysiology, clinical features, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Optic neuritis: Pathophysiology, clinical features, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Benjamin Osborne, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Laura J Balcer, MD, MSCE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francisco González-Scarano, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul W Brazis, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet L Wilterdink, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 28, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic neuritis is an inflammatory, demyelinating condition that causes acute, usually monocular, visual loss. It is highly associated with multiple sclerosis (MS). Optic neuritis is the presenting feature of MS in 15 to 20 percent of patients and occurs in 50 percent at some time during the course of their illness [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p>
         The term "optic neuritis" is sometimes applied to other inflammatory and infectious conditions affecting the optic nerve. These and other causes of optic neuropathy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5244.html" rel="external">
          "Optic neuropathies"
         </a>
         .)
        </p>
        <p>
         The epidemiology, pathophysiology, clinical features, and diagnosis of demyelinating optic neuritis will be covered here. Prognosis and treatment of optic neuritis and other clinical manifestations of MS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">
          "Optic neuritis: Prognosis and treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">
          "Manifestations of multiple sclerosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">
          "Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of acute demyelinating optic neuritis occur in females (two-thirds) and typically develop in patients between the ages of 20 and 40 years [
         <a href="#rid5">
          5-7
         </a>
         ].
        </p>
        <p>
         The incidence of optic neuritis is highest in populations located at higher latitudes, in the northern United States and western Europe, and is lowest in regions closer to the equator. In the United States, studies have estimated the annual incidence of optic neuritis to be as high as 6.4 per 100,000 [
         <a href="#rid8">
          8,9
         </a>
         ]. In the United States, optic neuritis occurs more frequently in White compared with Black Americans [
         <a href="#rid10">
          10
         </a>
         ]. In Asia, optic neuritis is proportionately more common relative to the incidence of multiple sclerosis (MS) than in the United States or Western Europe [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common pathologic basis for optic neuritis is inflammatory demyelination of the optic nerve. The pathology is similar to that of acute multiple sclerosis (MS) plaques in the brain, with perivascular cuffing, edema in the myelinated nerve sheaths, and myelin breakdown. Inflammation of the retinal vascular endothelium can precede demyelination and is sometimes visibly manifest as retinal vein sheathing [
         <a href="#rid12">
          12
         </a>
         ]. Myelin loss exceeds axonal loss.
        </p>
        <p>
         It is believed that the demyelination in optic neuritis is immune mediated, but the specific mechanism and target antigen(s) are unknown. Systemic T cell activation is identified at symptom onset and precedes changes in the cerebrospinal fluid (CSF) [
         <a href="#rid13">
          13
         </a>
         ]. Systemic changes also normalize earlier (within two to four weeks) than central changes. T cell activation leads to the release of cytokines and other inflammatory agents. B cell activation against myelin basic protein is not seen in peripheral blood but can be demonstrated in the CSF of patients with optic neuritis [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         As with MS, a genetic susceptibility for optic neuritis is suspected. This is supported by an over-representation of certain human leukocyte antigen (HLA) types among patients with optic neuritis [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Acute features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic neuritis is usually monocular in its clinical presentation. In approximately 10 percent of cases, symptoms occur in both eyes, either simultaneously or in rapid succession [
         <a href="#rid17">
          17
         </a>
         ]. Bilateral optic neuritis is more common in children younger than 12 to 15 years old; higher incidences have been reported in Black South African patients as well as in patients from Korea and Singapore [
         <a href="#rid17">
          17-22
         </a>
         ]. Because bilateral symptoms are relatively uncommon, they should suggest an alternative cause of optic neuropathy. However, subclinical visual deficits in acuity, contrast sensitivity, color vision, and visual field in the contralateral eye can often be elicited by detailed visual testing in patients with clinically monocular disease [
         <a href="#rid9">
          9,23
         </a>
         ]. Because these deficits usually resolve along with the clinical deficits in the symptomatic eye, it is unlikely that these findings represent prior episodes of optic neuritis.
        </p>
        <p>
         Other clinical features of optic neuritis were systematically characterized in the Optic Neuritis Treatment Trial (ONTT), which enrolled 457 patients, aged 18 to 46 years, with acute unilateral optic neuritis [
         <a href="#rid7">
          7,24
         </a>
         ]. The two most common symptoms of optic neuritis are vision loss and eye pain:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vision loss typically develops over a period of hours to days, peaking within one to two weeks. Continued deterioration after that time suggests an alternative diagnosis [
         <a href="#rid1">
          1,2
         </a>
         ]. Greater than 90 percent of patients in the ONTT had a significant decrease in central visual acuity. In most, the visual acuities ranged from 20/25 to 20/190 (median visual acuity 20/60). However, some patients had 20/20 acuity (11 percent), and, at the other extreme, a few had no light perception (3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eye pain occurred in 92 percent of patients in the ONTT and often worsened with eye movement [
         <a href="#rid7">
          7
         </a>
         ]. The onset of pain generally coincided with the visual acuity loss and improved along with it.
        </p>
        <p>
        </p>
        <p>
         Other common visual symptoms and signs include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An afferent pupillary defect always occurs in optic neuritis if the other eye is uninvolved and otherwise healthy. This is demonstrated by shining a light alternately in one eye and then the other and finding that the direct response to light is more sluggish in the affected eye. The room should be dark, and the patient should fixate on a distant target to prevent miosis due to accommodation. (See
         <a class="medical medical_review" href="/z/d/html/5095.html" rel="external">
          "The detailed neurologic examination in adults", section on 'Afferent pupillary defect'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The visual field defect in optic neuritis is typically characterized as a central scotoma [
         <a href="#rid1">
          1,25
         </a>
         ]. However, in the ONTT, almost all types of visual field defects were seen, including diffuse vision loss and altitudinal, arcuate, hemianopic, and cecocentral defects. Nonetheless, a defect that extends to the periphery should suggest a compressive lesion, while an altitudinal defect, particularly an inferior altitudinal defect, is more common in anterior ischemic optic neuropathy [
         <a href="#rid1">
          1,25
         </a>
         ]. Visual field defects usually resolve; in the ONTT, 56 percent had normalized at one year and 73 percent had normalized at 10 years [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Papillitis with hyperemia and swelling of the disk, blurring of disk margins, and distended veins is seen in one-third of patients with optic neuritis  (
         <a class="graphic graphic_picture graphicRef50320" href="/z/d/graphic/50320.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Two-thirds of these patients have retrobulbar neuritis with a normal funduscopic examination  (
         <a class="graphic graphic_picture graphicRef66013" href="/z/d/graphic/66013.html" rel="external">
          picture 2
         </a>
         ). Papillitis is more common in children less than 14 years old and in certain ethnic populations, including Black South Africans and patients from Korea and Singapore [
         <a href="#rid11">
          11,18-20
         </a>
         ]. Peripapillary hemorrhages are rare in optic neuritis but are a common accompaniment to papillitis due to anterior ischemic optic neuropathy [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with optic neuritis due to myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) frequently have bilateral papillitis, which may be mistaken for papilledema  (
         <a class="graphic graphic_figure graphicRef131854" href="/z/d/graphic/131854.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Photopsias (flickering or flashes of light) are often precipitated with eye movement and were reported by 30 percent of patients in the ONTT [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of color of vision out of proportion to the loss of visual acuity is specific to optic nerve pathology. Abnormal color vision by Ishihara plates was found in 88 percent of involved eyes in the ONTT; this increased to 94 percent with the more sensitive Farnsworth-Munsell 100 hue test [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other signs of ocular inflammation may be observed by the ophthalmologist on funduscopic or slit lamp examination. Perivenous sheathing or periphlebitis retinae can be seen in approximately 12 percent of patients with optic neuritis and implies a high risk for multiple sclerosis (MS) [
         <a href="#rid9">
          9,12
         </a>
         ]. Uveitis, cells in the anterior chamber, and/or pars planitis are uncommonly seen in optic neuritis and are more typical of infections and other autoimmune diseases. (See
         <a class="medical medical_review" href="/z/d/html/5244.html" rel="external">
          "Optic neuropathies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Chronic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even after clinical recovery, signs of optic neuritis can persist. These signs in a patient without a history of optic neuritis may suggest a previous, subclinical attack. When a patient presents with a possible first attack of MS elsewhere in the central nervous system, these signs are often sought because evidence of other demyelinating episodes separated in "time and space" can affect prognosis and treatment decisions. (See
         <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">
          "Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"
         </a>
         .)
        </p>
        <p>
         Chronic signs of optic neuritis can include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent visual loss. Most patients with optic neuritis recover functional vision within one year. However, on testing, deficits in color vision, contrast sensitivity, stereo acuity, and light brightness are detectable in most patients at up to two years [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">
          "Optic neuritis: Prognosis and treatment", section on 'Recovery of vision'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A relative afferent pupillary defect remains in approximately one-fourth of patients two years after presentation [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Color desaturation refers to a qualitative intereye difference in color perception that can be tested by comparing vision of a red object with each eye. A patient with monocular "red desaturation" may report that the red color appears "washed out," pink, or orange when viewed with the affected eye.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Temporary exacerbations of visual problems in patients can occur with increased body temperature (Uhthoff phenomenon). Hot showers and exercise are classic precipitants.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optic atrophy to at least some degree almost always follows an attack of optic neuritis, despite the return of visual acuity [
         <a href="#rid29">
          29
         </a>
         ]. Normal, 20/20 visual acuity requires less than one-half of normal foveal axons [
         <a href="#rid30">
          30
         </a>
         ]. The disc appears shrunken and pale, particularly in its temporal half (temporal pallor). The disk pallor extends beyond the margins of the disk into the peripapillary retinal nerve fiber layer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pattern-shift visual evoked response (VER) remains delayed in most patients, even with visual recovery. Although latencies continue to shorten (improve) up to two years after presentation, abnormalities are seen in most (80 percent) at two years [
         <a href="#rid28">
          28,31,32
         </a>
         ]. (See
         <a class="local">
          'Visual evoked response'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a young child, infectious and postinfectious causes of optic nerve impairment should be considered as alternatives to optic neuritis, while in an older patient (&gt;50 years), ischemic optic neuropathy (due, for example, to diabetes mellitus or giant cell arteritis) is a more likely diagnosis than optic neuritis.
        </p>
        <p>
         Alternative diagnoses should also be considered in patients with a bilateral presentation or those with other neurologic or systemic symptoms.
        </p>
        <p>
         In cases of recurrent optic neuritis that are not due to neuromyelitis optica (NMO), myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), or multiple sclerosis (MS), other causes of recurrent optic neuritis should be thoroughly investigated (such as sarcoidosis, lupus, chronic relapsing inflammatory optic neuropathy [CRION], or paraneoplastic optic neuropathy [serum CRMP5/CV2 antibody]).
        </p>
        <p>
         The differential diagnosis of optic nerve diseases is summarized in the tables and is discussed separately  (
         <a class="graphic graphic_table graphicRef75945" href="/z/d/graphic/75945.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef51786" href="/z/d/graphic/51786.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5244.html" rel="external">
          "Optic neuropathies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2890602403">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, optic neuritis is a clinical diagnosis based upon the history and examination findings. Because important findings on funduscopic examination help differentiate typical from atypical cases of optic neuritis, an ophthalmologic examination should be considered an essential feature of the clinical evaluation.
        </p>
        <p>
         Magnetic resonance imaging (MRI) study of the brain and orbits with gadolinium contrast provides confirmation of the diagnosis in most cases and also provides an assessment of the risk of subsequent multiple sclerosis (MS).
        </p>
        <p>
         Patients with recurrent or bilateral optic neuritis and those who present with additional neurologic signs or symptoms should undergo further evaluation to determine if the optic neuritis is due to a broader neurologic disease such as neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). (See
         <a class="local">
          'Antibody testing'
         </a>
         below.)
        </p>
        <p>
         Further diagnostic testing is directed toward excluding other causes of visual loss in atypical cases. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         An MRI study of the brain and orbits with gadolinium contrast provides confirmation of the diagnosis of acute demyelinating optic neuritis and important prognostic information regarding the risk of developing MS.
        </p>
        <p>
         Innovations in MRI technology (eg, short tau inversion recovery [STIR], fast spin echo [FSE], and fluid-attenuated inversion recovery with fat suppression techniques [FLAIR], diffusion tensor imaging [DTI]) have improved imaging of the optic nerve [
         <a href="#rid33">
          33-35
         </a>
         ]. Optic nerve inflammation can be demonstrated in approximately 95 percent of patients with optic neuritis with gadolinium contrast-enhanced MRI of the brain and orbits  (
         <a class="graphic graphic_diagnosticimage graphicRef69073" href="/z/d/graphic/69073.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid6">
          6,36-38
         </a>
         ]. The longitudinal extent of nerve involvement as seen on MRI correlates with visual impairment at presentation and with visual prognosis [
         <a href="#rid31">
          31,36,38
         </a>
         ]. Gadolinium enhancement persists for a mean of 30 days since onset [
         <a href="#rid31">
          31
         </a>
         ]. The signal abnormality in the nerve can still be seen after recovery of vision, and is also present in as many as 60 percent of patients with MS who do not have a clinical history of optic neuritis [
         <a href="#rid31">
          31,39-41
         </a>
         ].
        </p>
        <p>
         The brain MRI often shows white matter abnormalities characteristic of MS  (
         <a class="graphic graphic_diagnosticimage graphicRef81188" href="/z/d/graphic/81188.html" rel="external">
          image 2
         </a>
         ). Typical lesions are ovoid, periventricular, and larger than 3 mm (see
         <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">
          "Evaluation and diagnosis of multiple sclerosis in adults", section on 'Lesion characteristics'
         </a>
         ). The reported prevalence of white matter abnormalities varies substantially among patients with optic neuritis (23 to 75 percent) [
         <a href="#rid42">
          42
         </a>
         ]. In the ONTT, almost 40 percent of patients had MRI lesions, but this trial represents a selected patient group [
         <a href="#rid7">
          7
         </a>
         ]. Small case series of unselected patients have noted a higher coincidence of MRI brain lesions [
         <a href="#rid31">
          31,43,44
         </a>
         ]. Individuals with white matter abnormalities are at a higher risk of developing MS. (See
         <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">
          "Optic neuritis: Prognosis and treatment"
         </a>
         .)
        </p>
        <p>
         The yield of spinal cord imaging is low in unselected patients. Among 115 patients presenting with optic neuritis, MRI abnormalities in the spinal cord were seen in only four patients with a normal brain MRI [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Lumbar puncture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lumbar puncture is not an essential diagnostic test in optic neuritis but should be considered in atypical cases (eg, those with bilateral presentation, &lt;15 years in age, or symptoms suggesting infection) [
         <a href="#rid45">
          45,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5244.html" rel="external">
          "Optic neuropathies", section on 'Infections'
         </a>
         .)
        </p>
        <p>
         Approximately 60 to 80 percent of patients with acute optic neuritis have nonspecific abnormalities in the cerebrospinal fluid (CSF), including lymphocytes (10 to 100) and elevated protein [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Other CSF findings in optic neuritis can include [
         <a href="#rid47">
          47
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myelin basic protein in approximately 20 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin G (IgG) synthesis in 20 to 36 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oligoclonal bands (OCB) in 56 to 69 percent
        </p>
        <p>
        </p>
        <p>
         The presence of OCB implies a higher risk of developing MS. However, since OCB are also associated with white matter lesions on brain MRI, their presence is not clearly of independent prognostic importance [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">
          "Optic neuritis: Prognosis and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Other testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         When there are relevant clues to an alternative diagnosis  (
         <a class="graphic graphic_table graphicRef51786" href="/z/d/graphic/51786.html" rel="external">
          table 2
         </a>
         ), measurement of the erythrocyte sedimentation rate, antinuclear antibodies, and angiotensin converting enzyme levels and serologic and CSF tests for Lyme disease and syphilis should be obtained [
         <a href="#rid45">
          45,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5244.html" rel="external">
          "Optic neuropathies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Fluorescein angiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">
          Fluorescein
         </a>
         angiography is not routinely performed in the evaluation of optic neuritis and is often normal. Up to 25 percent demonstrate either dye leakage or perivenous sheathing [
         <a href="#rid12">
          12
         </a>
         ]. These findings may identify patients at somewhat higher risk for developing MS.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Visual evoked response
         </span>
         <span class="headingEndMark">
          —
         </span>
         A delay in the P100 of the visual evoked response (VER) is the electrophysiologic manifestation of slowed conduction in the optic nerve as a result of axonal demyelination [
         <a href="#rid48">
          48
         </a>
         ]. This test is not usually helpful in the diagnosis of acute optic neuritis, unless there is a suspicion that the visual loss is functional.
        </p>
        <p>
         Abnormalities in the VER can persist after recovery of full vision. At one year, 80 to 90 percent will be abnormal; 35 percent will return to normal at two years [
         <a href="#rid28">
          28,31,32
         </a>
         ]. The VER is often employed to find evidence of previous, asymptomatic episodes of optic neuritis, but the sensitivity and specificity are imperfect [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The multifocal VER is a technical advance that appears to be more sensitive and specific for identifying optic neuritis, but this technology is not generally available [
         <a href="#rid1">
          1,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Optical coherence tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optical coherence tomography (OCT) measures the thickness in the retinal nerve fiber layer and detects thinning in most (85 percent) of patients with optic neuritis [
         <a href="#rid48">
          48,50-53
         </a>
         ]. These abnormalities are also common in patients with MS who do not have a clinical history of optic neuritis [
         <a href="#rid54">
          54
         </a>
         ]. While lower values correlate with impaired visual outcome, the utility of OCT as a prognostic tool is limited in that abnormal values do not show up until early swelling disappears. In one study, OCT was less sensitive than VER in detecting subclinical optic neuritis [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         A number of studies have found that a greater severity of optic nerve injury seen on OCT suggests neuromyelitis optica (NMO) rather than optic neuritis associated with MS [
         <a href="#rid56">
          56-58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Antibody testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum NMO antibody testing (both aquaporin-4 autoantibody and MOG antibody) is suggested for individuals with recurrent optic neuritis, particularly if the MRI brain is negative for any abnormal T2/FLAIR lesions outside of the affected optic nerve(s) [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Patients with recurrent optic neuritis appear to be particularly at risk for NMOSD or MOGAD. This is particularly true for patients with a normal brain MRI and those with optic neuritis events in rapid succession or with a presentation of severe vision loss [
         <a href="#rid60">
          60
         </a>
         ]. In one series of 51 patients with either severe or recurrent optic neuritis, six patients were seropositive for the aquaporin-4-specific serum autoantibody, a sensitive biomarker for NMO, while 10 patients were seropositive for antibodies to MOG, which has also been associated with NMO [
         <a href="#rid61">
          61-64
         </a>
         ]. In other studies, seropositivity for the aquaporin-4-specific serum autoantibody was predictive of subsequent NMO among patients with recurrent optic neuritis [
         <a href="#rid65">
          65,66
         </a>
         ]. MOG antibody testing is recommended for patients with recurrent optic neuritis who test negative for aquaporin-4-specific serum autoantibody.
        </p>
        <p>
         Other features of optic neuritis that suggest MOGAD are papillitis and bilateral, longitudinally extensive enhancement of the optic nerves (especially the anterior segments) and optic nerve sheaths on contrast-enhanced MRI.
        </p>
        <p>
         Rare patients should be tested for glial fibrillary acidic protein (GFAP) by measuring GFAP antibodies in the serum and CSF. GFAP astrocytopathy may cause optic neuritis (frequently papillitis) [
         <a href="#rid67">
          67
         </a>
         ]. In addition, patients may present with encephalopathy, headache, or transverse myelitis. The MRI brain with contrast sometimes shows a unique pattern of linear radial enhancement along the perivascular vessels, perpendicular to the lateral ventricles.
        </p>
        <p>
         The clinical features and diagnosis of NMOSDs and MOGAD are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">
          "Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">
          "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3607362243">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">
          "Society guideline links: Multiple sclerosis and related disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H348623100">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83437.html" rel="external">
          "Patient education: Optic neuritis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Optic neuritis is an acute inflammatory demyelinating injury to the optic nerve.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In typical cases, painful, monocular visual loss evolves over several hours to a few days. One-third of patients have visible optic nerve inflammation on funduscopic examination (papillitis); in the remainder, the inflammation is retrobulbar. (See
         <a class="local">
          'Acute features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Chronic signs of optic neuritis include a relative afferent pupillary defect, color desaturation, and optic atrophy. These often persist despite recovery of normal vision. (See
         <a class="local">
          'Chronic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – The diagnosis of optic neuritis is made in the setting of unilateral painful loss of vision in an adult younger than 50 years old. An ophthalmologic examination is an essential feature of the clinical evaluation. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Magnetic resonance imaging (MRI) study of the brain and orbits with gadolinium contrast provides confirmation of the diagnosis in most cases and also provides an assessment of the risk of subsequent multiple sclerosis (MS). (See
         <a class="local">
          'Magnetic resonance imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other tests, including lumbar puncture,
         <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">
          fluorescein
         </a>
         angiography, and visual evoked potentials, are used in atypical cases. Antibody testing is recommended for patients with recurrent optic neuritis and those with neurologic or MRI features suggesting a neuromyelitis optica spectrum disorder (NMOSD) or other antibody-associated disease. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Common entities in the differential diagnosis of optic neuritis are presented in the tables  (
         <a class="graphic graphic_table graphicRef75945" href="/z/d/graphic/75945.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef51786" href="/z/d/graphic/51786.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5244.html" rel="external">
          "Optic neuropathies"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol 2002; 13:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 2005; 139:1101.
          </a>
         </li>
         <li class="breakAll">
          Liu GT. Visual loss: optic neuropathies. In: Neuro-Ophthalmology: Diagnosis and Management, Liu GT, Volpe NJ, Galetta SL (Eds), WB Saunders, Philadelphia 2001.
         </li>
         <li class="breakAll">
          Wray SH. Optic neuritis. In: Principles and Practice of Ophthalmology, Albert DM, Jakobiec FA (Eds), WB Saunders, Philadelphia 1994. p.2539.
         </li>
         <li>
          <a class="nounderline abstract_t">
           The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1991; 109:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis. An epidemiologic study. Arch Ophthalmol 1972; 87:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995; 45:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakakura M, Minei-Higa R, Oono S, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999; 43:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lightman S, McDonald WI, Bird AC, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987; 110 ( Pt 2):405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roed H, Frederiksen J, Langkilde A, et al. Systemic T-cell activation in acute clinically isolated optic neuritis. J Neuroimmunol 2005; 162:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Söderström M, Link H, Xu Z, Fredriksson S. Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. Neurology 1993; 43:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frederiksen JL, Madsen HO, Ryder LP, et al. HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings. Arch Neurol 1997; 54:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 1987; 50:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol 2006; 90:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pokroy R, Modi G, Saffer D. Optic neuritis in an urban black African community. Eye (Lond) 2001; 15:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwang JM, Lee YJ, Kim MK. Optic neuritis in Asian children. J Pediatr Ophthalmol Strabismus 2002; 39:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang JC, Tow S, Aung T, et al. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Exp Ophthalmol 2001; 29:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucchinetti CF, Kiers L, O'Duffy A, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilejto M, Shroff M, Buncic JR, et al. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006; 67:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck RW, Kupersmith MJ, Cleary PA, Katz B. Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology 1993; 100:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck RW. The Optic Neuritis Treatment Trial. Arch Ophthalmol 1988; 106:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerling J, Meyer JH, Kommerell G. Visual field defects in optic neuritis and anterior ischemic optic neuropathy: distinctive features. Graefes Arch Clin Exp Ophthalmol 1998; 236:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol 1994; 112:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004; 137:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brusa A, Jones SJ, Plant GT. Long-term remyelination after optic neuritis: A 2-year visual evoked potential and psychophysical serial study. Brain 2001; 124:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleary PA, Beck RW, Bourque LB, et al. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuroophthalmol 1997; 17:18.
          </a>
         </li>
         <li class="breakAll">
          Miller NR, Newman NJ, Biousse V, Kerrison JB. Walsh and Hoyt's Clinical Neuro-ophthalmology, Lippincott, Williams and Wilkins, Philadelphia 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hickman SJ, Toosy AT, Miszkiel KA, et al. Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004; 251:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celesia GG, Kaufman DI, Brigell M, et al. Optic neuritis: a prospective study. Neurology 1990; 40:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker GJ. Technical issues for the study of the optic nerve with MRI. J Neurol Sci 2000; 172 Suppl 1:S13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson A, Sheppard S, Laitt RD, et al. Optic neuritis: MR imaging with combined fat- and water-suppression techniques. Radiology 1998; 206:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naismith RT, Xu J, Tutlam NT, et al. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 2009; 72:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzo JF 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109:1679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocca MA, Hickman SJ, Bö L, et al. Imaging the optic nerve in multiple sclerosis. Mult Scler 2005; 11:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain 2002; 125:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youl BD, Turano G, Towell AD, et al. Optic neuritis: swelling and atrophy. Electroencephalogr Clin Neurophysiol Suppl 1996; 46:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller DH, Newton MR, van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology 1988; 38:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies MB, Williams R, Haq N, et al. MRI of optic nerve and postchiasmal visual pathways and visual evoked potentials in secondary progressive multiple sclerosis. Neuroradiology 1998; 40:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalton CM, Brex PA, Miszkiel KA, et al. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry 2003; 74:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997; 41:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Städt D, Kappos L, Rohrbach E, et al. Occurrence of MRI abnormalities in patients with isolated optic neuritis. Eur Neurol 1990; 30:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol 2003; 18:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck RW, Trobe JD. What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology 1995; 102:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 2005; 252:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klistorner A, Arvind H, Nguyen T, et al. Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol 2008; 64:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraser CL, Klistorner A, Graham SL, et al. Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology 2006; 113:323.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005; 58:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006; 113:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Seze J, Blanc F, Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol 2008; 65:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh EA, Marrie RA, Reginald YA, et al. Functional-structural correlations in the afferent visual pathway in pediatric demyelination. Neurology 2014; 83:2147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 2009; 73:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009; 72:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009; 73:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green AJ, Cree BA. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry 2009; 80:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 2010; 81:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pirko I, Blauwet LA, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol 2004; 61:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Hernandez E, Sepulveda M, Rostásy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol 2015; 72:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmoukou K, Alexopoulos H, Akrivou S, et al. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2015; 2:e131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pache F, Zimmermann H, Mikolajczak J, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 2016; 13:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dos Passos GR, Oliveira LM, da Costa BK, et al. MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. Front Neurol 2018; 9:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70:2197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takagi M, Tanaka K, Suzuki T, et al. Anti-aquaporin-4 antibody-positive optic neuritis. Acta Ophthalmol 2009; 87:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunchok A, Zekeridou A, McKeon A. Autoimmune glial fibrillary acidic protein astrocytopathy. Curr Opin Neurol 2019; 32:452.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5251 Version 14.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16554529" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical practice. Optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441840" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acute demyelinating optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15664543" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The neuro-ophthalmology of multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15953446" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evolving management of optic neuritis and multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15953446" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Evolving management of optic neuritis and multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15953446" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Evolving management of optic neuritis and multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1841573" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5057861" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Optic neuritis and multiple sclerosis. An epidemiologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7854520" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Optic neuritis: a population-based study in Olmsted County, Minnesota.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482360" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Optic neuritis in African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10340795" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3567529" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15833372" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Systemic T-cell activation in acute clinically isolated optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7513391" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9006417" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3497228" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16622084" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical profile of simultaneous bilateral optic neuritis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11767021" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Optic neuritis in an urban black African community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11859913" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Optic neuritis in Asian children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11720158" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The presentation, aetiology, management and outcome of optic neuritis in an Asian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9371931" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Risk factors for developing multiple sclerosis after childhood optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16864818" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The clinical features, MRI findings, and outcome of optic neuritis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8493012" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3041942" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The Optic Neuritis Treatment Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9541821" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Visual field defects in optic neuritis and anterior ischemic optic neuropathy: distinctive features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8031275" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14700647" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11222447" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Long-term remyelination after optic neuritis: A 2-year visual evoked potential and psychophysical serial study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093956" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093956" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15316805" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2345615" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Optic neuritis: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10606799" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Technical issues for the study of the optic nerve with MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9423652" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Optic neuritis: MR imaging with combined fat- and water-suppression techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19073948" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12208717" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16193891" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Imaging the optic nerve in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11912114" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9059791" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Optic neuritis: swelling and atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3340276" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Magnetic resonance imaging of the optic nerve in optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9877128" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : MRI of optic nerve and postchiasmal visual pathways and visual evoked potentials in secondary progressive multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14617723" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Spinal cord MRI in clinically isolated optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9066361" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2289505" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Occurrence of MRI abnormalities in patients with isolated optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15513003" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Optic neuritis in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9097798" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : What we have learned from the Optic Neuritis Treatment Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15778816" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18825673" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Axonal loss and myelin in early ON loss in postacute optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16406544" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16718705" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Quantifying axonal loss after optic neuritis with optical coherence tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16075460" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16406539" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18625858" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Optical coherence tomography in neuromyelitis optica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25361777" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Functional-structural correlations in the afferent visual pathway in pediatric demyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19564583" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19307541" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636050" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19465415" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20019228" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364686" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The natural history of recurrent optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25506781" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptorα1 subunit in patients with isolated optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26185777" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27802824" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29670575" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18434643" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : NMO-IgG predicts the outcome of recurrent optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19021599" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Anti-aquaporin-4 antibody-positive optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30724768" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Autoimmune glial fibrillary acidic protein astrocytopathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
